Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1997 Dec;35(12):3274–3277. doi: 10.1128/jcm.35.12.3274-3277.1997

Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.

S A Villano 1, D Vlahov 1, K E Nelson 1, C M Lyles 1, S Cohn 1, D L Thomas 1
PMCID: PMC230161  PMID: 9399533

Abstract

Between 1988 and 1996, the incidence of and risk factors for hepatitis C virus (HCV) infection were studied in a cohort of injection drug users in Baltimore, Maryland. By second-generation antibody testing of stored serum samples, 142 participants were found to be susceptible to HCV at the time they entered the study. After a median follow-up of 6.5 years, 43 participants (30.3%) developed antibodies to HCV (anti-HCV). The overall incidence was 6.4 cases per 100 person-years, but a substantial decline in the annual incidence rate was observed after the first 2 years (1988 to 1990, 13.4/100 person-years; 1991 to 1996, 2.3/100 person-years [P = 0.0001 for trend]). Participants who acknowledged active drug use, especially those who acknowledged frequent use and sharing of drug paraphernalia, were at increased risk of HCV infection. However, high-risk sexual practices were not associated with HCV seroconversion. Efforts to reduce HCV infection must be focused on curbing drug use and especially on the sharing of needles and drug paraphernalia.

Full Text

The Full Text of this article is available as a PDF (125.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter M. J. Epidemiology of hepatitis C in the West. Semin Liver Dis. 1995 Feb;15(1):5–14. doi: 10.1055/s-2007-1007259. [DOI] [PubMed] [Google Scholar]
  2. Alter M. J., Hadler S. C., Judson F. N., Mares A., Alexander W. J., Hu P. Y., Miller J. K., Moyer L. A., Fields H. A., Bradley D. W. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA. 1990 Nov 7;264(17):2231–2235. [PubMed] [Google Scholar]
  3. Alter M. J., Margolis H. S., Krawczynski K., Judson F. N., Mares A., Alexander W. J., Hu P. Y., Miller J. K., Gerber M. A., Sampliner R. E. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992 Dec 31;327(27):1899–1905. doi: 10.1056/NEJM199212313272702. [DOI] [PubMed] [Google Scholar]
  4. Cacopardo B., Fatuzzo F., Cosentino S., Celesia B. M., Mughini M. T., La Rosa R., Bruno S., Lupo G., Zipper F., La Medica G. HCV and HIV infection among intravenous drug abusers in eastern Sicily. Arch Virol Suppl. 1992;4:333–334. doi: 10.1007/978-3-7091-5633-9_77. [DOI] [PubMed] [Google Scholar]
  5. Chamot E., de Saussure P., Hirschel B., Déglon J. J., Perrin L. H. Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS. 1992 Apr;6(4):430–431. [PubMed] [Google Scholar]
  6. Di Bisceglie A. M., Goodman Z. D., Ishak K. G., Hoofnagle J. H., Melpolder J. J., Alter H. J. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 1991 Dec;14(6):969–974. doi: 10.1016/0270-9139(91)90113-a. [DOI] [PubMed] [Google Scholar]
  7. Donahue J. G., Nelson K. E., Muñoz A., Vlahov D., Rennie L. L., Taylor E. L., Saah A. J., Cohn S., Odaka N. J., Farzadegan H. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol. 1991 Nov 15;134(10):1206–1211. doi: 10.1093/oxfordjournals.aje.a116023. [DOI] [PubMed] [Google Scholar]
  8. Galeazzi B., Tufano A., Barbierato E., Bortolotti F. Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. Liver. 1995 Aug;15(4):209–212. doi: 10.1111/j.1600-0676.1995.tb00672.x. [DOI] [PubMed] [Google Scholar]
  9. Gerberding J. L. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis. 1994 Dec;170(6):1410–1417. doi: 10.1093/infdis/170.6.1410. [DOI] [PubMed] [Google Scholar]
  10. Hagan H., Jarlais D. C., Friedman S. R., Purchase D., Alter M. J. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995 Nov;85(11):1531–1537. doi: 10.2105/ajph.85.11.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kiyosawa K., Sodeyama T., Tanaka E., Gibo Y., Yoshizawa K., Nakano Y., Furuta S., Akahane Y., Nishioka K., Purcell R. H. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990 Oct;12(4 Pt 1):671–675. doi: 10.1002/hep.1840120409. [DOI] [PubMed] [Google Scholar]
  12. Kiyosawa K., Sodeyama T., Tanaka E., Nakano Y., Furuta S., Nishioka K., Purcell R. H., Alter H. J. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med. 1991 Sep 1;115(5):367–369. doi: 10.7326/0003-4819-115-5-367. [DOI] [PubMed] [Google Scholar]
  13. Levine O. S., Vlahov D., Brookmeyer R., Cohn S., Nelson K. E. Differences in the incidence of hepatitis B and human immunodeficiency virus infections among injecting drug users. J Infect Dis. 1996 Mar;173(3):579–583. doi: 10.1093/infdis/173.3.579. [DOI] [PubMed] [Google Scholar]
  14. Mitsui T., Iwano K., Masuko K., Yamazaki C., Okamoto H., Tsuda F., Tanaka T., Mishiro S. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology. 1992 Nov;16(5):1109–1114. [PubMed] [Google Scholar]
  15. Nelson K. E., Vlahov D., Solomon L., Cohn S., Muñoz A. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md. Arch Intern Med. 1995 Jun 26;155(12):1305–1311. [PubMed] [Google Scholar]
  16. Rezza G., Sagliocca L., Zaccarelli M., Nespoli M., Siconolfi M., Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scand J Infect Dis. 1996;28(1):27–29. doi: 10.3109/00365549609027145. [DOI] [PubMed] [Google Scholar]
  17. Seeff L. B., Beebe G. W., Hoofnagle J. H., Norman J. E., Buskell-Bales Z., Waggoner J. G., Kaplowitz N., Koff R. S., Petrini J. L., Jr, Schiff E. R. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med. 1987 Apr 16;316(16):965–970. doi: 10.1056/NEJM198704163161601. [DOI] [PubMed] [Google Scholar]
  18. Terrault N. A., Wright T. L. Hepatitis C virus in the setting of transplantation. Semin Liver Dis. 1995 Feb;15(1):92–100. doi: 10.1055/s-2007-1007266. [DOI] [PubMed] [Google Scholar]
  19. Thomas D. L., Vlahov D., Solomon L., Cohn S., Taylor E., Garfein R., Nelson K. E. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995 Jul;74(4):212–220. doi: 10.1097/00005792-199507000-00005. [DOI] [PubMed] [Google Scholar]
  20. Tong M. J., el-Farra N. S., Reikes A. R., Co R. L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995 Jun 1;332(22):1463–1466. doi: 10.1056/NEJM199506013322202. [DOI] [PubMed] [Google Scholar]
  21. Van Ameijden E. J., Van den Hoek J. A., Mientjes G. H., Coutinho R. A. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol. 1993 May;9(3):255–262. doi: 10.1007/BF00146260. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES